| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10211932 | Clinical Lymphoma Myeloma and Leukemia | 2018 | 9 Pages |
Abstract
The shorter overall survival with secondary HS suggests a more aggressive course than that with de novo disease. Larger scale studies are needed to further investigate the biology and genetics of HS.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Devin R. Broadwater, Joanna L. Conant, David R. Czuchlewski, Jordan M. Hall, Shi Wei, Gene P. Siegal, Deniz Peker,